Julian Matschinske

Julian Matschinske

Auto-generated profile, based on publicly available information

Julian Matschinske

Institute for Computational Systems Biology, University of Hamburg , Hamburg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
AMAndreas Maier
Andreas Maier
MHMichael Hartung
Michael Hartung
MAMark Abovsky
Mark Abovsky
KAKlaudia Adamowicz
Klaudia Adamowicz
GBGary Bader
Gary Bader
Jan BaumbachJan Baumbach
Jan Baumbach
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.

12 July 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JMJulian Matschinske
Julian Matschinske
Background: Machine learning and artificial intelligence have shown promising results in many areas and are driven by the increasing amount of available data. However, these data are often distributed across different institutions and cannot be easily shared owing to strict privacy regulations. Federated learning (FL) allows the training of distributed machine learning models without sharing sensitive data. In addition, the implementation is time-consuming and requires advanced programming skills and complex technical infrastructures. Objective: Various tools and frameworks have been developed to simplify the development of FL algorithms and provide the necessary technical infrastructure. Although there are many high-quality frameworks, most focus only on a single application case or method. To our knowledge, there are no generic frameworks, meaning that the existing solutions are restricted to a particular type of algorithm or application field. Furthermore, most of these frameworks provide an application programming interface that needs programming knowledge. There is no collection of ready-to-use FL algorithms that are extendable and allow users (eg, researchers) without programming knowledge to apply FL. A central FL platform for both FL algorithm developers and users does not exist. This study aimed to address this gap and make FL available to everyone by developing FeatureCloud, an all-in-one platform for FL in biomedicine and beyond. Methods: The FeatureCloud platform consists of 3 main components: a global frontend, a global backend, and a local controller. Our platform uses a Docker to separate the local acting components of the platform from the sensitive data systems. We evaluated our platform using 4 different algorithms on 5 data sets for both accuracy and runtime. Results: FeatureCloud removes the complexity of distributed systems for developers and end users by providing a comprehensive platform for executing multi-institutional FL analyses and implementing FL algorithms. Through its integrated artificial intelligence store, federated algorithms can easily be published and reused by the community. To secure sensitive raw data, FeatureCloud supports privacy-enhancing technologies to secure the shared local models and assures high standards in data privacy to comply with the strict General Data Protection Regulation. Our evaluation shows that applications developed in FeatureCloud can produce highly similar results compared with centralized approaches and scale well for an increasing number of participating sites. Conclusions: FeatureCloud provides a ready-to-use platform that integrates the development and execution of FL algorithms while reducing the complexity to a minimum and removing the hurdles of federated infrastructure. Thus, we believe that it has the potential to greatly increase the accessibility of privacy-preserving and distributed data analyses in biomedicine and beyond.

6 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RNReza Nasirigerdeh
Reza Nasirigerdeh
RTReihaneh Torkzadehmahani
Reihaneh Torkzadehmahani
JMJulian Matschinske
Julian Matschinske
TFTobias Frisch
Tobias Frisch
MLMarkus List
Markus List
Jan BaumbachJan Baumbach
Jan Baumbach
Genome-wide association studies (GWAS) have been widely used to unravel connections between genetic variants and diseases. Larger sample sizes in GWAS can lead to discovering more associations and more accurate genetic predictors. However, sharing and combining distributed genomic data to increase the sample size is often challenging or even impossible due to privacy concerns and privacy protection laws such as the GDPR. While meta-analysis has been established as an effective approach to combine summary statistics of several GWAS, its accuracy can be attenuated in the presence of cross-study heterogeneity. Here, we present sPLINK ( safe PLINK ), a user-friendly tool, which performs federated GWAS on distributed datasets while preserving the privacy of data and the accuracy of the results. sPLINK neither exchanges raw data nor does it rely on summary statistics. Instead, it performs model training in a federated manner, communicating only model parameters between cohorts and a central server. We verify that the federated results from sPLINK are the same as those from aggregated analyses conducted with PLINK . We demonstrate that sPLINK is robust against heterogeneous data (phenotype and confounding factors) distributions across cohorts while existing meta-analysis tools considerably lose accuracy in such scenarios. We also show that sPLINK achieves practical runtime, in order of minutes or hours, and acceptable network bandwidth consumption for chi-square and linear/logistic regression tests. Federated analysis with sPLINK , thus, has the potential to replace meta-analysis as the gold standard for collaborative GWAS. The user-friendly, readily usable sPLINK tool is available at https://exbio.wzw.tum.de/splink .

12 September 2022 in JMIR Preprints
Verified
Preprint
Open access
JMJulian Matschinske
Julian Matschinske
JSJulian Späth
Julian Späth
MBMohammad Bakhtiari
Mohammad Bakhtiari
NPNiklas Probul
Niklas Probul
MMMohammad Mahdi Kazemi Majdabadi
Mohammad Mahdi Kazemi Majdabadi
Jan BaumbachJan Baumbach
Jan Baumbach
BACKGROUND Machine learning and artificial intelligence have shown promising results in many areas and are driven by the increasing amount of available data. However, these data are often distributed across different institutions and cannot be easily shared owing to strict privacy regulations. Federated learning (FL) allows the training of distributed machine learning models without sharing sensitive data. In addition, the implementation is time-consuming and requires advanced programming skills and complex technical infrastructures. OBJECTIVE Various tools and frameworks have been developed to simplify the development of FL algorithms and provide the necessary technical infrastructure. Although there are many high-quality frameworks, most focus only on a single application case or method. To our knowledge, there are no generic frameworks, meaning that the existing solutions are restricted to a particular type of algorithm or application field. Furthermore, most of these frameworks provide an application programming interface that needs programming knowledge. There is no collection of ready-to-use FL algorithms that are extendable and allow users (eg, researchers) without programming knowledge to apply FL. A central FL platform for both FL algorithm developers and users does not exist. This study aimed to address this gap and make FL available to everyone by developing FeatureCloud, an all-in-one platform for FL in biomedicine and beyond. METHODS The FeatureCloud platform consists of 3 main components: a global frontend, a global backend, and a local controller. Our platform uses a Docker to separate the local acting components of the platform from the sensitive data systems. We evaluated our platform using 4 different algorithms on 5 data sets for both accuracy and runtime. RESULTS FeatureCloud removes the complexity of distributed systems for developers and end users by providing a comprehensive platform for executing multi-institutional FL analyses and implementing FL algorithms. Through its integrated artificial intelligence store, federated algorithms can easily be published and reused by the community. To secure sensitive raw data, FeatureCloud supports privacy-enhancing technologies to secure the shared local models and assures high standards in data privacy to comply with the strict General Data Protection Regulation. Our evaluation shows that applications developed in FeatureCloud can produce highly similar results compared with centralized approaches and scale well for an increasing number of participating sites. CONCLUSIONS FeatureCloud provides a ready-to-use platform that integrates the development and execution of FL algorithms while reducing the complexity to a minimum and removing the hurdles of federated infrastructure. Thus, we believe that it has the potential to greatly increase the accessibility of privacy-preserving and distributed data analyses in biomedicine and beyond.

26 August 2022
Verified
Conference Paper
Open access
SSSepideh Sadegh
Sepideh Sadegh
JMJulian Matschinske
Julian Matschinske
DBDavid B. Blumenthal
David B. Blumenthal
GGGihanna Galindez
Gihanna Galindez
TKTim Kacprowski
Tim Kacprowski
Jan BaumbachJan Baumbach
Jan Baumbach
In a pandemic, such as the one caused by the coronavirus in 2020, fast action is required to provide insights into the disease mechanisms and to find potential drug targets to slow the progress of the disease and lower mortality. We developed CoVex, an interactive online platform for the exploration of the SARS-CoV-2 host interactome and the identification of drug candidates. CoVex integrates the virus-human protein interactions, human protein-protein interactions, and drug-target interactions, and allows for visual exploration of the data. The exploration is guided by network-based systems medicine algorithms that enable the assembly of ranked lists of candidates for already approved drugs. Unlike novel drugs, approved drugs have the advantage that most of their side effects and contraindications are known. Additionally, they are already available and can be distributed quickly, which makes them promising candidates to stop the uncontrolled spread of the disease early. CoVex is an example of how this could be achieved in future pandemics and provides valuable lessons on what is required in such a situation to maximize the potential of computational approaches that can significantly speed up drug discovery.

26 August 2022
Verified
Conference Paper
Open access
PDF file
MHMichael Hartung
Michael Hartung
AMAndreas Maier
Andreas Maier
SSSepideh Sadegh
Sepideh Sadegh
JMJulian Matschinske
Julian Matschinske
MLMarkus List
Markus List
Jan BaumbachJan Baumbach
Jan Baumbach
Heterogeneous biological networks are an efficient way to represent interaction systems of biomedical entities such as disease modules or drug-protein interactomes. Online resources for multi-omics analyses and other biomedical tools have to either develop a suitable network representation for their results or to omit this feature. This results in a large variety of custom solutions of different quality for network visualization and network-enhanced drug repurposing prediction. We developed Drugst.One, a customizable plug-and-play solution for biomedical web-application developers in need of a feature-rich network explorer closing the gap between gene sets or modules and drugs. Drugst.One integrates multiple databases to complement visualized data, and network algorithms for drug target identification and drug repurposing analyses. Given lists of genes, proteins or small networks, Drugst.One instantly enriches the input with biomedical information such as protein-,drug-protein interactions, and disease associations. Network algorithms enable users to conduct follow-up analyses by connecting scattered proteins, by identifying additional drug targets as well as by ranking drugs regarding their repurposing potential. The lightweight and fully customizable plug-in can be integrated into any web application with just a few lines of code that developers can generate even automatically using the Drugst.One web code generator. Its components and functions are adjustable to fit the host web pages' purpose and style. “Drugst.One” buttons allow the integration into any existing network analysis web tool without the need to integrate the plugin into the website. Drugst.One is available at https://drugst.one/ and as a python package at https://pypi.org/project/drugstone/.